WHAT IS CLAIMED:

1. Use of an anti-CDH6 antibody-drug conjugate for the manufacture of a medicament for treating or preventing cancer, the antibody-drug conjugate comprising an anti-CDH6 antibody and an antitumor compound connected by a linker, wherein the linker and the antitumor compound are represented by the following formula:

-(Succinimid-3-yl-N)-$CH_2CH_2CH_2CH_2CH_2$-C(=O)-GGFG-NH-CH_2-O-CH_2-C(=O)-(NH-DX)

wherein -(Succinimid-3-yl-N)- has a structure represented by the following formula:



which is connected to the antibody at position 3 thereof and is connected to a methylene group in the linker structure containing this structure on the

nitrogen atom at position 1, and (NH-DX) represents a group represented by the following formula:



wherein the nitrogen atom of the amino group at position 1 is the connecting position, wherein the anti-CDH6 antibody comprises CDRH1 consisting of the amino acid sequence of SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence of SEQ ID NO: 60 and CDRH3 consisting of the amino acid sequence of SEQ ID NO: 19 in its heavy chain variable region and CDRL1 consisting of the amino acid sequence of SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence of SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence of SEQ ID NO: 14 in its light chain variable region,

wherein a dose of the antibody-drug conjugate in a range of 3.2 mg/kg to 9.6 mg/kg is to be administered to a subject.

2. The use according to claim 1, wherein the antibody comprises a heavy chain variable region comprising amino acids sequence of SEQ ID NO: 71 and a light chain variable region comprising amino acids sequence of SEQ ID NO: 63.

3. The use according to claim 1 or 2, wherein the antibody-drug conjugate has a structure represented by the following formula:



wherein Ab is an antibody comprising a heavy chain variable region comprising SEQ ID NO: 71 and a light

chain variable region comprising SEQ ID NO: 63, and n represents the average number of units of the drug-linker structure conjugated to the antibody per antibody, wherein n is in the range of from 1 to 10.

4. The use according to any one of claims 1 to 3, wherein the antibody comprises a heavy chain comprising the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69 and a light chain comprising the amino acid sequence at positions 21 to 233 in SEQ ID NO: 61.

5. The use according to any one of claims 1 to 4, wherein the heavy chain or the light chain has undergone one or two or more modifications selected from the group consisting of N-linked glycosylation, O-linked glycosylation, N-terminal processing, C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, addition of a methionine residue to the N-terminus, amidation of

a proline residue, conversion of N-terminal glutamine or N-terminal glutamic acid to pyroglutamic acid, and a deletion of one or two amino acids from the carboxyl terminus.

6. The use according to any one of claims 1 to 5, wherein the anti-CDH6 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

7. The use according to any one of claims 1 to 6, wherein an average number of units of the antitumor compound conjugated per antibody is in a range of from 2 to 8, preferably wherein an average number of units of the antitumor compound conjugated per antibody is 7 to 8.

8. The use according to any one of claims 1 to 7, wherein the dose of the antibody-drug conjugate is in a range of 4.8 mg/kg to 9.6 mg/kg, 3.2 mg/kg to 8.0 mg/kg, 3.2 mg/kg to 6.4 mg/kg, 4.8 mg/kg to 8.0 mg/kg or 4.8 mg/kg to 6.4 mg/kg.

9. The use according to any one of claims 1 to 7, wherein the dose of the antibody-drug conjugate is about 3.2 mg/kg, about 4.8 mg/kg, about 5.4 mg/kg, about 5.6 mg/kg, about 6.4 mg/kg or about 8.0 mg/kg

10. The use according to any one of claims 1 to 7, wherein the dose of the antibody-drug conjugate is 3.2 mg/kg, 3.3 mg/kg, 3.4 mg/kg, 3.5 mg/kg, 3.6 mg/kg, 3.7 mg/kg, 3.8 mg/kg, 3.9 mg/kg, 4.0 mg/kg, 4.1 mg/kg, 4.2 mg/kg, 4.3 mg/kg, 4.4 mg/kg, 4.5 mg/kg, 4.6 mg/kg, 4.7 mg/kg, 4.8 mg/kg, 4.9 mg/kg, 5.0 mg/kg, 5.1 mg/kg, 5.2 mg/kg, 5.3 mg/kg, 5.4 mg/kg, 5.5 mg/kg, 5.6 mg/kg, 5.7 mg/kg, 5.8 mg/kg, 5.9 mg/kg, 6.0 mg/kg, 6.1 mg/kg, 6.2 mg/kg, 6.3 mg/kg or 6.4 mg/kg.

11. The use according to any one of claims 1 to 7, wherein the dose of the antibody-drug conjugate is selected from the group consisting of: 4.8 mg/kg to

6.4 mg/kg, about 4.8 mg/kg, about 5.6 mg/kg, about 6.4 mg/kg, 4.8 mg/kg, 5.6 mg/kg and 6.4 mg/kg.

12. The use according to any one of claims 1 to 11, wherein the medicament is to be administered by intravenous administration.

13. The use according to any one of claims 1 to 12, wherein the medicament is to be administered once every 3 weeks.

14. The use according to any one of claims 1 to 13, wherein the cancer is selected from the group consisting of renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, clear cell carcinoma of ovary, endometrioid carcinoma of ovary, ovarian mucinous tumor, thyroid cancer, bile duct cancer, lung cancer, non-small cell lung cancer, cervix cancer, brain tumor, head and neck cancer, sarcoma, osteosarcoma, small cell lung cancer,

glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor, neuroblastoma, colorectal cancer, gastric cancer, endometrial cancer, nasopharyngeal cancer, prostate cancer or cancers associated with von Hippel-Lindau disease.

15. The use according to claim 14, wherein the cancer is renal cell carcinoma, renal clear cell carcinoma or papillary renal cell carcinoma.

16. The antibody-drug conjugate according to claim 14, wherein the cancer is ovarian cancer, preferably wherein the ovarian cancer is selected from the group consisting of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

17. The use according to any one of claims 1 to 16, wherein the cancer is metastatic.

18. The use according to any one of claims 1 to 17, wherein the cancer is resistant or refractory.

19. The use according to claim 18, wherein the resistance or refractoriness is resistance or refractoriness acquired by the cancer due to treatment with an anticancer drug, preferably wherein the anticancer drug is a platinum-based chemotherapeutic, a chemotherapeutic, a PARP inhibitor, an immune checkpoint inhibitor, an angiogenic inhibitor or a VEGFR-TKI.

20. The use according to any one of claims 1 to 19, wherein the subject has a history of treatment with one or two or more anticancer drugs selected from the group consisting of a platinum-based chemotherapeutic, a chemotherapeutic, a PARP inhibitor, an immune checkpoint inhibitor, an angiogenic inhibitor and a VEGFR-TKI.

21. The use according to claim 19, wherein the anticancer drug is a platinum-based chemotherapeutic, preferably wherein the platinum-

based chemotherapeutic comprises a platinum-based drug and a taxane.

22. The use according to any one of claims 1 to 21, wherein the cancer is a CDH6-expressing cancer, preferably wherein the CDH6-expressing cancer is CDH6-overexpressing cancer.

23. The use according to any one of claims 1 to 22, wherein the cancer is an inoperable or recurrent cancer.

24. The use according to any one of claims 1 to 23, wherein the subject exhibits a recurrence of the cancer prior to administration of the antibody-drug conjugate.

25. The use according to claim 24, wherein the recurrence of the cancer occurs in less than or within about six months of completion of a chemotherapy regimen selected from the group consisting of the following:

(a) a chemotherapy regimen comprising a platinum-based drug, and

(b) a chemotherapy regimen comprising a platinum-based drug and a taxane.

26. The use according to claim 24, wherein the recurrence of the cancer occurs in or after about six months of completion of a chemotherapy regimen selected from the group consisting of the following:

(a) comprising a platinum-based drug, and

(b) a chemotherapy regimen comprising a platinum-based drug and a taxane.

27. The use according to any one of claims 1 to 26, wherein the antibody-drug conjugate is to be administered as monotherapy.

28. The use according to any one of claims 1 to 26, wherein the subject is to be administered the medicament with a second drug, preferably wherein

the medicament is to be administered prior to, after, or concurrently with the second drug.

29. The use according to any one of claims 1 to 26, wherein the medicament is to be administered as a therapy selected from the group consisting of the following:

(a) as maintenance therapy,

(b) as adjuvant therapy,

(c) after surgical resection of the tumor,

(d) as neoadjuvant therapy, and

(e) prior to surgical resection of the tumor.

30. Use of an anti-CDH6 antibody-drug conjugate for the manufacture of a medicament for treating or preventing cancer, the anti-CDH6 antibody-drug conjugate having the structure represented by the following formula:



wherein AB represents an anti-CDH6 antibody, n represents the average number of units of the drug-linker structure conjugated to the antibody per antibody, and the antibody is connected to the linker via a sulfhydryl group derived from the antibody; wherein n is 7 to 8, wherein the antibody comprises: the heavy chain amino acid sequence represented by SEQ ID NO: 87 or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 87 in which one or two amino acids are deleted from the carboxyl terminus thereof; and the light chain amino acid sequence represented by SEQ ID NO: 88, wherein a dose of the antibody-drug conjugate is in a range of

4.8 mg/kg to 6.4 mg/kg, wherein the antibody-drug conjugate is to be administered by intravenous administration, wherein the antibody-drug conjugate is to be administered once every 3 weeks, and optionally wherein the anti-CDH6 antibody-drug conjugate is a salt thereof or a hydrate of the anti-CDH6 antibody-drug conjugate or the salt.

31. A pharmaceutical composition containing the antibody-drug conjugate as defined in any one of claims 1 to 30 or a salt thereof as an active component, and a pharmaceutically acceptable formulation component.

32. The use according to any one of claims 1 to 30, wherein the medicament is to be administered in a pharmaceutical composition comprising at least one pharmaceutically acceptable formulation component.